Clinical Trials

  • The World Health Organization reported that 1.8 million people from around the world were newly infected with HIV in 2016. An HIV vaccine is the best long-term hope for ending AIDS. We are looking for healthy, 18-60 year old and HIV-negative people to join a study we are conducting by first learning about the study followed by completing a screening process to find out if you meet study criteria. You are not committing to join a study by agreeing to screen for it.
  • Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to complete a brief online questionnaire at your leisure to find out if you meet basic study criteria.
  • Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to complete a brief online questionnaire at your leisure to find out if you meet basic study criteria.
  • The purpose of this research is to find out whether an experimental drug called maribivar is safe, and whether it is more effective than the medications we usually use to treat resistant CMV infections. Half of the people who choose to be part of this research study will be given maribivar, and half will be treated according to their physicians usual practice. The groups will be assigned by chance, like by a toss of a coin.The majority of people at some time in their life become infected with CMV but do not know they have it.
  • We are looking for HIV-negative individuals 18 to 60 years old who are interested in learning more about HIV prevention research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1-hour education visit to learn about the research we do. The education visit will help you decide if you want to participate in one of our studies. You will be compensated for the visit. Your responses to this questionnaire will be kept strictly confidential. We are currently enrolling into this study.
  • This research is being done to learn whether organ transplantation from HIV-positive deceased donors is as safe and effective in HIV-positive recipients as transplants from HIV-negative deceased donors. People with end-stage organ disease and HIV infection, and who qualify for organ transplantation, mayjoin this study.
  • We are doing this research study to find out how HIV infection affects oral health, including the gums, the number of teeth and the jaw bone (alveolar bone). To answer this question, we will compare people with or without HIV infection. About 240 women and 100 men are expected to be enrolled in this study at Columbia University Medical Center. Estamos realizando este estudio de investigacion para saber como la infeccion por VIH afecta la salud oral, incluidas las encias, el numero de dientes y el hueso de la mandibula (hueso alveolar).
  • We are doing this research study to find out how HIV infection affects oral health, including the gums, the number of teeth and the jaw bone (alveolar bone). To answer this question, we will compare people with or without HIV infection. About 240 women and 100 men are expected to be enrolled in this study at Columbia University Medical Center. Estamos realizando este estudio de investigacion para saber como la infeccion por VIH afecta la salud oral, incluidas las encias, el numero de dientes y el hueso de la mandibula (hueso alveolar).
  • The study is looking for postmenopausal women between the ages of 35-70 years that have moderate periodontitis for a 1 year long study which provides free dental cleaning. There are a total of 5 study visits, each one about 2 hours long, and each study visit provides you with $50, for a total of $250.
  • The MK-8228-002 Study is studying the safety and effectiveness of an investigational medication for preventing cytomegalovirus (CMV) disease in adults with kidney transplants. The MK-8228-002 Study is evaluating an investigational medication (known as MK-8228) versus valganciclovir (VGCV). VGCV is an antiviral medication and is the current standard of care for CMV disease prevention in kidney transplant recipients. The study will last for approximately one year (52 weeks). Study treatment will start within seven days post-transplant and continue through 28 weeks.